Arcellx, Kite aim to keep chipping away at Carvykti advantage with new multiple myeloma data: #ASH23

09 Dec 2023

Clinical ResultPhase 1ASCOASH

SAN DIEGO — Arcellx raised the curtain on the CAR-T data it will present on Monday at the American Society of Hematology conference as it readies a multiyear plan to take on J&J and Legend Biotech’s Carvykti, as well as Bristol Myers Squibb’s Abecma. Data from a Phase I multiple myeloma study for Arcellx’s anito-cel, formerly known as CART-ddBCMA, showed a 100% overall response rate in 38 evaluable patients, including 29 (76%) with a complete response. Additionally, in a group of 28 patients evaluable for minimal residual disease (MRD) testing, median duration of response, progression-free survival and overall survival measures have not yet been reached.

For more details,please visit the original website

The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.

Organizations

Arcellx, Inc.

Johnson & Johnson

Legend Biotech Corp.

[+1]

Indications

Multiple Myeloma

Targets

Drugs

Anbalcabtagene autoleucelAnti-BCMA CAR T-cell therapy(Arcellx, Inc.)

Hot reports

Global Drug R&D Express (Apr 2024)

PatSnap Synapse

Global Drug R&D Express (Mar 2024)

PatSnap Synapse

Global Drug R&D Express (Feb 2024)

PatSnap Synapse

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.